-+ 0.00%
-+ 0.00%
-+ 0.00%

UBS Maintains Neutral on Myriad Genetics, Lowers Price Target to $3.6

Benzinga·09/09/2026 18:05:18
Listen to the news
UBS analyst Lu Li maintains Myriad Genetics (NASDAQ:MYGN) with a Neutral and lowers the price target from $6 to $3.6.